Sofinnova Crossover I cuts Abivax (ABVX) holding to 3.1% after share sales

Rhea-AI Filing Summary

Sofinnova Crossover I SLP and related parties filed Amendment No. 6 to their Schedule 13D on Abivax S.A. after a series of open‑market sales of American depositary shares (ADSs) and ordinary shares on NASDAQ and Euronext.

Between June 30 and July 6, 2026, Sofinnova sold blocks of ADSs and ordinary shares at weighted average prices mostly above $130 per share. Following these transactions, Sofinnova held 2,474,299 ordinary shares, representing about 3.1% of Abivax’s outstanding ordinary shares, and 3,535,843 voting rights, or about 4.3% of outstanding voting rights as of May 31, 2026.

The filing emphasizes that Sofinnova acquired its position for investment purposes but may buy or sell additional Abivax securities over time, and that individual investment committee members disclaim beneficial ownership beyond their economic interest.

Key Figures

ADS sale June 30, 2026: 500,000 ADSs at $132.7347 ADS sale July 1, 2026: 25,000 ADSs at $134.2377 Ordinary share sale July 2, 2026: 35,469 shares at $144.2752 +5 more

8 metrics

ADS sale June 30, 2026 500,000 ADSs at $132.7347 Open-market sale on June 30, 2026 at weighted average price per ADS

ADS sale July 1, 2026 25,000 ADSs at $134.2377 Open-market sale on July 1, 2026 at weighted average price per ADS

Ordinary share sale July 2, 2026 35,469 shares at $144.2752 Open-market sale; euro price converted using $1.1448 rate

Ordinary share sales July 3, 2026 25,000 at $156.2041; 39,531 at $155.0654 Two tranches of ordinary shares sold on July 3, 2026

Remaining ordinary shares 2,474,299 shares Held directly by Sofinnova Crossover I SLP as of July 6, 2026

Voting rights held 3,535,843 voting rights Approximately 4.3% of Abivax voting rights as of May 31, 2026

Abivax shares outstanding 79,782,941 ordinary shares Ordinary shares outstanding used to compute 3.1% ownership as of May 31, 2026

Abivax voting rights outstanding 82,130,598 voting rights Baseline for calculating Sofinnova’s 4.3% voting-right stake as of May 31, 2026

Key Terms

Schedule 13D, beneficially owns, voting rights, American depositary shares, +2 more

6 terms

Schedule 13D regulatory

"This Amendment No. 6 … amends and supplements the filed with the Securities and Exchange Commission…"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficially owns financial

"The Reporting Person beneficially owns 2,474,299 Ordinary Shares…"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

voting rights financial

"…and has 3,535,843 voting rights related to such shares."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

American depositary shares financial

"…including ordinary shares represented by American depositary shares…"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"…at a weighted average price of $132.7347 per share."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

investment committee financial

"…the members of the investment committee of SC…"

An investment committee is a small group of experienced people who set the rules and make the key decisions about what investments to buy, hold, or sell for a fund, pension, or portfolio. Think of them as the steering team that balances goals, potential returns and risk—their choices shape how much money investors are likely to gain or lose and provide consistent oversight so decisions aren’t made impulsively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/06/2026 - 09:36 PM Accepted by SEC EDGAR 07/06/2026 - 09:35 PM Learn about SEC filing dates

FAQ

What does Abivax (ABVX) disclose about Sofinnova’s current ownership stake?

Sofinnova Crossover I SLP now holds 2,474,299 Abivax ordinary shares, about 3.1% of shares outstanding. It also controls 3,535,843 voting rights, approximately 4.3% of total voting rights based on May 31, 2026 figures.

What recent Abivax (ABVX) share sales did Sofinnova report in this Schedule 13D/A?

Sofinnova reported open‑market sales of Abivax ADSs and ordinary shares between June 30 and July 6, 2026. Transactions included a 500,000 ADS sale at a $132.7347 weighted average price and several euro‑denominated ordinary share sales converted into U.S. dollars.

At what prices did Sofinnova sell Abivax (ABVX) ADSs and shares?

Reported weighted average prices included $132.7347 and $134.2377 per ADS, and converted U.S. dollar prices such as $140.9365, $144.2752, $155.0654, $155.0436, and $156.2041 per ordinary share for trades completed in late June and early July 2026.

How many Abivax (ABVX) ADSs did Sofinnova sell on June 30 and July 1, 2026?

On June 30, 2026 Sofinnova sold 500,000 Abivax ADSs at a weighted average price of $132.7347 per share. On July 1, 2026 it sold a further 25,000 ADSs at a weighted average price of $134.2377 per share.

What outstanding share and voting-right figures are used in this Abivax (ABVX) Schedule 13D/A?

Ownership percentages are based on 79,782,941 Abivax ordinary shares and 82,130,598 voting rights outstanding as of May 31, 2026. Sofinnova’s 2,474,299 shares equal 3.1% of shares; its 3,535,843 voting rights equal 4.3% of total voting rights.

How do Sofinnova’s investment committee members relate to Abivax (ABVX) share ownership?

Sofinnova Partners SAS manages Sofinnova Crossover I SLP and may share voting and investment control over Abivax securities. Investment committee members are Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat, who each disclaim beneficial ownership beyond their pecuniary interest.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Abivax S.A.

(Name of Issuer)

Ordinary Shares, par value EUR0.01 per share

(Title of Class of Securities)

00370M103

(CUSIP Number)

Armance Bordes
7-11, boulevard Haussmann,
Paris, I0, 75009
33 1 76 23 41 09

John Partigan
Nixon Peabody LLP, 799 9 Street NW Ste 500
Washington, DC, 20001
202-585-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Sofinnova Crossover I SLP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Crossover I SLP ("SC"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat"), the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Sofinnova Partners SAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Note in relation to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares. Note in relation to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Antoine Papiernik

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Cedric Moreau

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FRANCE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Kinam Hong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Joseph Anderson

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

CUSIP Number(s): 00370M103

1

Name of reporting person

Jacques Theurillat

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,535,843.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,474,299.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

3,535,843.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Note to Items 7 and 8: SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares. Note to Items 9 and 10: SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares. Note in relation to Items 8, 10, 11 and 13: The Reporting Person beneficially owns 2,474,299 Ordinary Shares (including ordinary shares represented by American depositary shares) and has 3,535,843 voting rights related to such shares. The aggregate amount beneficially owned and percent of class reported above are based on the Reporting Person's voting rights and the 82,130,598 voting rights outstanding as of May 31, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, par value EUR0.01 per share
(b)	Name of Issuer: Abivax S.A.
(c)	Address of Issuer's Principal Executive Offices: 7-11, boulevard Haussmann, Paris, FRANCE , 75009.
Item 1 Comment: Introductory Statement: This Amendment No. 6 (this "Amendment"), being filed by Sofinnova Crossover I SLP ("SC"), Sofinnova Partners SAS, a French corporation ("SP SAS"), Antoine Papiernik ("Papiernik"), Cedric Moreau ("Moreau"), Kinam Hong ("Hong"), Joseph Anderson ("Anderson") and Jacques Theurillat ("Theurillat") the members of the investment committee of SC (collectively, the "Listed Persons" and together with SC and SP SAS, the "Reporting Persons"), amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on October 30, 2023, as amended by Amendment No. 1, filed with the SEC on February 14, 2025, as further amended by Amendment No. 2, filed with the SEC on July 31, 2025, as amended by Amendment No. 3, filed with the SEC on October 30, 2025, as further amended by Amendment No. 4, filed with the SEC on January 14, 2026, and as further amended by Amendment No. 5, filed with the SEC on May 11, 2026 (collectively, as amended, the "Schedule 13D"). This Schedule 13D relates to the Ordinary Shares, par value EUR0.01 per share (the "Ordinary Shares"), including ordinary shares represented by American Depositary Shares ("ADS"), of Abivax SA, a societe anonyme incorporated under the laws of the French Republic (the "Issuer"). Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.
Item 2.	Identity and Background
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: SC sold the amounts of ADS and Ordinary Shares on the date and at the prices set forth below in open market transactions on NASDAQ and Euronext. All daily sales of the shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each weighted average price set forth in this Schedule 13D. June 30, 2026: -500,000 ADSs at a weighted average price of $132.7347 per share. July 1, 2026: -25,000 ADSs at a weighted average price of $134.2377 per share. July 2, 2026: -275,000 ADSs at a weighted average price of $140.9365 per share.* -35,469 Ordinary Shares at a weighted average price of $144.2752 per share.* July 3, 2026: -25,000 Ordinary Shares at a weighted average price of $156.2041 per share.* -39,531 Ordinary Shares at a weighted average price of $155.0654 per share.* July 6, 2026: -3,195 Ordinary Shares at a weighted average price of $155.0436 per share.* * Transaction completed in Euros. Price per share converted to USD at an exchange rate of $1.1448 as of July 3, 2026. All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals which would be related to or would result in any of the matters described in Items 4(a)-(j) of the Instructions to Schedule 13D. However, as part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider such matters and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: As of July 6, 2026, SC held directly 2,474,299 Ordinary Shares representing approximately 3.1% of the Issuer's outstanding Ordinary Shares and 3,535,843 voting rights representing approximately 4.3% of the Issuer's outstanding voting rights. None of the other Reporting Persons hold any Ordinary Shares or ADSs directly. SP SAS is the management company of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat are the members of the investment committee of SC and may be deemed to have shared voting and investment control over the Ordinary Shares and ADSs held by SC. Each of such individuals disclaims beneficial ownership of such Ordinary Shares and ADSs except to the extent of their pecuniary interest therein. The ownership percentages are based upon 79,782,941 of the Issuer's Ordinary Shares outstanding as of May 31, 2026. The voting percentages are based upon 82,130,598 voting rights outstanding as of May 31, 2026.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except as disclosed herein, there have been no other reportable transactions with respect to the Ordinary Shares or ADSs of the Issuer within the last 60 days by the Reporting Persons.
Item 7.	Material to be Filed as Exhibits.
	EX 99.1 - Agreement regarding filing of joint Schedule 13D (incorporated by reference from Exhibit 99.1 to Schedule 13D filed by the Reporting Persons on October 30, 2023)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sofinnova Crossover I SLP

Signature:	/s/ Antoine Papiernik
Name/Title:	Authorized Representative
Date:	07/06/2026

Sofinnova Partners SAS

Signature:	/s/ Antoine Papiernik
Name/Title:	Managing Partner
Date:	07/06/2026

Antoine Papiernik

Signature:	/s/ Antoine Papiernik
Name/Title:	Antoine Papiernik
Date:	07/06/2026

Cedric Moreau

Signature:	/s/ Cedric Moreau
Name/Title:	Cedric Moreau
Date:	07/06/2026

Kinam Hong

Signature:	/s/ Kinam Hong
Name/Title:	Kinam Hong
Date:	07/06/2026

Joseph Anderson

Signature:	/s/ Joseph Anderson
Name/Title:	Joseph Anderson
Date:	07/06/2026

Jacques Theurillat

Signature:	/s/ Jacques Theurillat
Name/Title:	Jacques Theurillat
Date:	07/06/2026